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AbsTrACT
Provide the state of the art concerning (1) biology and 
aetiology, (2) classification, (3) clinical assessment and (4) 
conservative treatment of lower limb muscle injuries (MI) in 
athletes. Seventy international experts with different medical 
backgrounds participated in the consensus conference. 
They discussed and approved a consensus composed of 
four sections which are presented in these documents. This 
paper represents a synthesis of the consensus conference, 
the following four sections are discussed: (i) The biology and 
aetiology of MIs. A definition of MI was formulated and some 
key points concerning physiology and pathogenesis of MIs 
were discussed. (ii) The MI classification. A classification 
of MIs was proposed. (iii) The MI clinical assessment, in 
which were discussed anamnesis, inspection and clinical 
examination and are provided the relative guidelines. (iv) 
The MI conservative treatment, in which are provided the 
guidelines for conservative treatment based on the severity 
of the lesion. Furthermore, instrumental therapy and 
pharmacological treatment were discussed. Knowledge of 
the aetiology and biology of MIs is an essential prerequisite 
in order to plan and conduct a rehabilitation plan. Another 
important aspect is the use of a rational MI classification 
on prognostic values. We propose a classification based on 
radiological investigations performed by ultrasonography 
and MRI strongly linked to prognostic factors. Furthermore, 
the consensus conference results will able to provide 
fundamental guidelines for diagnostic and rehabilitation 
practice, also considering instrumental therapy and 
pharmacological treatment of MI. Expert opinion, level IV.
InTroduCTIon
Muscle injuries (MI) are the most common 
trauma both in team and individual sports 
and are responsible for most of the time lost 
in both training and competition.1–3 In profes-
sional football (soccer), they account for 
30%4 and in track and field 48% of all inju-
ries recorded.1 In soccer, the muscle groups 
most prone to injury are the hamstrings (37% 
of all the MIs),1–5 followed by the adductors 
(23%),4 rectus femoris (19%)4 and calf muscles 
(13%).4 6 However, despite the strong interest 
of clinicians and researchers in this topic, there 
is still no consensus conference (CC) which 
simultaneously covered the aetiopathogenesis, 
classification, clinical examination and treat-
ment of MIs.3 6 
bACkground of ITAlIAn Consensus 
ConferenCe on guIdelInes for ConservATIve 
TreATmenT on lower lImb InjurIes In 
AThleTe
The ﬁrst ‘Italian Consensus Conference on 
Guidelines for Conservative Treatment on 
Lower Limb Injuries in Athlete’ was organ-
ised by the Italian Society of Arthroscopy in 
Milan, on 8 April 2017, with the participa-
tion of 70 national experts with different 
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medical backgrounds: orthopaedic surgeons (25), 
sports physicians (8), radiologists (5), rehabilitation 
physicians (3), sport physiologists (3), general surgeons 
(2), family physicians (2), physiotherapists (11) and 
physical trainers (11). The selection was based on their 
Hirsch index, the number of publications concerning 
MI and experience in the clinical evaluation, medical 
treatment and rehabilitation of MI. The experts did 
not represent any organisations. All experts who partic-
ipated in the CC are included as authors of this report. 
Three authors (EC, KC and ZV) though not present at 
CC were invited to give their intellectual contribution 
to the study.
This paper represents the synthesis of the Italian Consensus 
Conference on Guidelines for Conservative Treatment on Lower 
Limb Injuries in Athlete, while the complete document (about 
200 pages in Italian language) can be consulted at the official 
website of the Italian Society of Arthroscopy ().
CC lITerATure revIew proCess
Prior to the CC, two senior authors (GNB and PV) 
performed a systematic literature review on the biology 
and aetiology, classification, clinical evaluation and 
conservative treatment of MI. The review process was 
conducted as follows:
1. An independent research was performed inde-
pendently by two authors, with no language limitation 
applied.
2. Databases used were MEDLINE, EMBASE, EXCERPTA 
MEDICA, Cochrane Central Register of Controlled 
Trials and Cochrane Database of Systematic Review. 
The so-called ‘grey literature’ (ie, conferences, ab-
stracts, thesis and unpublished reports) was not taken 
into consideration.
Following the review, all studies that did not report rele-
vant information to the above-mentioned four speciﬁc 
clinical points were excluded.
After the review, the authors provided a comprehensive 
summary document divided into four distinct sections: 
(1) biology and aetiology; (2) classification; (3) clinical 
evaluation; and (4) conservative treatment regarding MI. 
This document was delivered in advance (7 days) to each 
expert participating at the CC and was considered as a 
starting point for the discussion. The two senior authors 
had the role of facilitator (GNB) and chairman (PV) 
during the CC.
CC presenTATIon
All the CC participants approved the four following 
sections of the summary document:
1. Biology and aetiology of MI.
2. MI classification.
3. MI clinical assessment.
4. MI conservative treatment.
During the discussion, each document was initially 
presented by the facilitator (GNB), followed by a plenary 
discussion guided by the chairman (PV), and finally 
approved by a vote.
The CC participants voted for each document, util-
ising a Likert scale of 0–10, where 0 reﬂected complete 
disagreement, 5 neither agreement nor disagree-
ment and 10 complete agreement. The discussions 
continued until a mean score of >7.5 was reached7 8 and 
the voting process enabled the chairman to interrupt 
the discussion if in his opinion final decision could 
not be reached. The ﬁrst document required three 
separate discussions and three voting rounds, while 
the second, third and fourth documents required 17, 
1 and 4 discussions of subparts and voting rounds, 
respectively. During the discussions, the document 
was modified and then the ﬁnal version was voted 
on. Consensus was reached in all cases at the end of 
each discussion phase, where the majority of partici-
pants reached an agreement (ie, when a mean score 
of >7.5 was reached). The voting results are shown 
in tables 1–4.
Table 1  The results of the different voting rounds 
concerning document 1 (biology and aetiology of muscle 
injury document consensus)
Voting (n=3) Score
Voting 1 9.2±0.5
Voting 2 9.6±0.4
Voting 3 9.4±0.5
Table 2  The results of the different voting rounds 
concerning document 2 (muscle injury classification 
document consensus)
Voting (n=17) Score
Voting 1 9.4±0.5
Voting 2 9±0.6
Voting 3 8.8±0.6
Voting 4 9±0.5
Voting 5 9.2±0.4
Voting 6 9.2±0.5
Voting 7 9±0.6
Voting 8 9.2±0.3
Voting 9 9.2±0.5
Voting 10 9.2±0.5
Voting 11 9.2±0.5
Voting 12 9.2±0.5
Voting 13 9.2±0.5
Voting 14 9.2±0.5
Voting 15 9.2±0.5
Voting 16 9.4±0.4
Voting 17 9.2±0.5
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seCTIon 1. summAry of bIology And AeTIology of mI 
doCumenT Consensus
Few authors have explicitly defined the term ‘muscular 
injury’, although some have attempted to correlate the 
concept of injury to that of loss of proper muscle func-
tions.9 10 However, identifying MI with the simple loss of 
function is not entirely correct, since muscle function can 
be affected by events such as fatigue or atrophy, which 
has nothing to do with the injury mechanism. For these 
reasons, during the CC, we formulated the following defi-
nition of muscle lesion:
‘MI is a loss of function caused by a damage of the anatomical 
structure that generates (muscle) and transmits (tendon) force.’
key points
The central role of eccentric contraction in the 
pathogenesis of indirect MI (indMI; ie, a lesion 
due to an overstretching of the muscle fibres) was 
underlined.9 11–15 Furthermore, the significance of 
overlapping mechanical causes11–18 and metabolic path-
ways was discussed.19–21 The importance of the calcium 
overload stage and the consequent self-aggravation 
of the lesion in the immediate postinjury period was 
stressed.21–23 Finally, the importance of the role of stem 
cells (SC) in skeletal muscle repair and regeneration 
processes was also discussed24–29 and, in agreement with 
other studies,28 29 the use of stem cells as treatment for 
MIs was disapproved because scientific evidence does 
not confirm its effectiveness and safety.
The importance of three different phases when 
planning conservative treatment programmes was 
acknowledged: (1) destruction phase, (2) repair phase 
and (3) remodelling phase.27 30–32
seCTIon 2. summAry of mI ClAssIfICATIon doCumenT 
Consensus
We provide guidance on:
i. The classification of indMI.
ii. The classification of direct MI (dirMI; ie, an injury 
caused by a blunt trauma at muscle belly level).
iii. The timing of imaging exams.
The classification of mI
Classification should respect the following points:
i. It must be reproducible.
ii. It must provide a clear distinction between different 
categories.
iii. It must be easy to remember.
iv. It must be concise and easily understandable.
v. It must be linked to prognostic factors.
The CC, carrying out a synthesis of the main and most 
recent classifications in literature,33–48 proposed the 
following classification for the indMI, subdividing it in 
accordance with the radiological investigation performed 
by ultrasonography (US) or MRI.
staging of indmI by us examination
Delayed muscle soreness
The delayed-onset muscle soreness (DOMS) does not 
give any US abnormalities. Diagnosis should therefore 
be based on the clinical examination, and imaging is 
not recommended for 48 hours. DOMS is to be consid-
ered as a substructural (ie, not detectable by radiological 
examination) lesion of the muscle, although due to a 
physiological adaptation.49
Clinical-history criteria
i. The athlete has no recollection of any injury event. 
ii. The pain appears about 24–48 hours after the trig-
gering event (training or competition). 
iii. The pain is usually bilateral.
iv. The athlete does not indicate a specific point of pain, 
but rather the entire muscle belly.
v. Usually, the athlete feels pain at rest as well as 
during the activity which includes minimal muscle 
activation.
vi. Usually, the pain decreases after warm-up and during 
training sessions.
vii. The triggering event is usually a high-intensity 
training session or competition, related to unusual 
exercises often with high eccentric loading, or from 
unfavourable environmental conditions such as par-
ticularly heavy playing grounds.
Prognosis
The usual return to full participation to training and 
competition (RFPTC) prognosis for DOMS (with 
optimal treatment) is between 48 and 72 hours. In case 
of extremely severe DOMS, the prognosis for RFPTC is 
subjective.
Fatigue-induced muscular disorder
Fatigue-induced muscular disorder (FIMD) is a substruc-
tural lesion normally not causing US abnormalities, 
although occasionally there may be a slight change in 
structural echogenicity.
Table 3  The results of the different voting rounds 
concerning document 3 (muscle injury clinical assessment 
document consensus)
Voting (n=1) Score
Voting 1 9.5±0.4
Table 4  The results of the different voting rounds 
concerning document 4 (muscle injury conservative 
treatment document consensus)
Voting (n=4) Score
Voting 1 9.0±0.5
Voting 2 9.0±0.5
Voting 3 9.0±0.6
Voting 4 9.0±0.5
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Clinical-anamnestic criteria
i. In FIMD the athlete does not correlate onset of pain 
to a precise movement and/or situation.
ii. In opposite to DOMS, symptomatology is usually 
monolateral. 
iii. In opposite to DOMS, initial cramping is often 
perceived during the game, or the symptoms are per-
ceived at the end of the activity.
iv. In opposite to DOMS, pain is not perceived at rest 
but only during activity.
v. The athlete does not indicate a precise point of pain, 
rather an extensive muscle area but still less than the 
entire muscular belly.
Prognosis
The prognosis for RFPTC in the case of FIMD (with 
optimal treatment) is 3–5 days.
Grade 0 lesion (indMI 0°)
Given the difficulty of detecting objective oedema 
through US examination and especially given the 
impossibility of differentiating an oedema from a haem-
orrhagic zone, especially in small lesions, the ‘grade 0’ 
staging via US examination is not advisable.
Grade I lesion (indMI I°)
The indMI I° is as macroscopic (ie, detectable by radio-
logical examination) structural damage.
Clinical-anamnestic criteria
i. The onset is acute and can be referred to a precise 
event.
ii. In most cases, the athlete is unable to continue the 
sporting activity he is engaged in.
iii. Pain, localised and well reproducible, is perceived 
during activity only.
US imaging criteria
The US shows a lesion at the primary and secondary 
muscle fascicles and the presence of a haematoma. The 
lesion extension has a diameter smaller than that of a 
secondary fascicle (ie, less than 5 mm). Perifascial liquid 
can be present.
Prognosis
The prognosis for RFPTC (with optimal treatment) is 
about 15 days.
Grade II lesion (indMI II°)
The indMI II° is as a macroscopic structural damage.
Clinical-anamnestic criteria
i. The onset is acute and can be traced back to a very 
precise event.
ii. In almost all cases, the athlete fails to continue the 
sporting activity in which he is engaged, and often 
has to stop immediately. 
iii. Localised and well-reproducible pain is often 
perceived at rest. Sports activities are impossible.
US imaging criteria
There is a substantial muscle discontinuity area, 
associated with a visible haematoma distal and proximal to 
the lesion. The extension of the lesion involves more than 
one secondary fascicle (ie, greater than 5 mm). Muscle 
areas adjacent to the injured zone appear to be hyperecho-
genic. Commonly, a considerable amount of intermuscular, 
perifascial and subcutaneous fluid collection is observed.
Often, a heterogeneous haematoma may overshadow 
the terminal tendon area, increasing the difficulty in 
reaching a precise diagnosis. In these cases, the terminal 
tendon area is better observed by MRI exam. 
Sometimes, it is objectively difficult to differentiate an 
indMI grade I from II by MRI exam.50 In these cases, the 
US exam is a valuable complementary tool to confirm 
the accuracy of the lesion18 45 50 with the possibility that 
the US itself allows to highlight the macroscopic struc-
tural alterations of the muscle at the level of the lesion 
site occurring during an eccentric dynamic contraction 
(during which the US imaging shows an increase in the 
lesion gap) typical of the grade II lesions.45 50
Prognosis
The prognosis for RFPTC (with optimal treatment) has 
been estimated to be between 20 and 60 days.
Grade III lesion (indMI III°)
IndMI III° is a macroscopic structural damage.
Clinical-anamnestic criteria
i. The onset is acute and can be traced back to a very 
precise event by the athlete.
ii. In all cases, the athlete is forced to stop the sport-
ing activity in which he is engaged, at the time of the 
injury.
iii. The pain, localised and well reproducible, is also per-
ceived at rest.
iv. Sports activities are impossible.
US imaging criteria
In US examination, an indMI III° involves more than 
85% of the total muscle diameter. Muscle areas adjacent 
to the lesion zone are hyperechogenic. Commonly, a 
considerable amount of intermuscular, perifascial and 
subcutaneous fluid collection is observed.
Prognosis
With optimal treatment the prognosis for RFPTC can 
be estimated between 60 and 90 days (in cases of serious 
injuries of muscles particularly involved in the sporting 
activity).
staging of indmI by mrI examination
Delayed-onset muscle soreness 
Clinical-anamnestic criteria
The criteria stated for the US exam remain valid.
MRI criteria
A low-grade DOMS does not involve alterations of the MRI 
signal either in the anatomic or fluid-sensitive sequences. 
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There may sometimes be transient oedema with no trace 
of blood. On the contrary, in the case of extremely severe 
DOMS, oedema in fluid-sensitive sequences appears to be 
superimposable to the one present in the case of indMI 
I°–II° (without fascicle damages) and persist for a period 
that may last even for 80 days.
Fatigue-induced muscular disorder 
Clinical-anamnestic criteria
The criteria stated for the US exam remain valid.
MRI criteria
FIMD generally does not result in alteration of the MRI 
signal neither in the anatomic nor in fluid-sensitive 
sequences. Transient oedema with no trace of blood may 
occasionally be present. The difference between DOMS 
and DMFI is therefore in principal basically based on the 
clinical-anamnestic investigation.
Prognosis
The criteria given for the US examination remain valid.
Grade 0 lesion (indMI 0°)
The indMI 0° is a substructural MI with functional conse-
quences and not a macroscopic structural damage.
Clinical-anamnestic criteria
i. The athlete can recall of a traumatic event in a repro-
ducible anatomically well-located point.
ii. The athlete is often able to continue the sports 
activity.
iii. Pain is not felt at rest but only during the activity.
MRI criteria
No macroscopic alterations in the muscular architecture 
are visible. There is a muscle oedema without disconti-
nuity of the fibres and without the presence of blood. 
The absence of blood is the comparative parameter that 
allows differentiating indMI 0° from an indMI I°.
Prognosis
With optimal treatment the prognosis for RFPTC is about 
8 days.
Grade I lesion (indMI I°)
The indMI I° is a macroscopic structural damage.
Clinical-anamnestic criteria
The clinical-anamnestic criteria identified for the US 
exam remain valid.
MRI criteria
An increased signal within the lesion zone is visible in 
high-contrast gradient sequences (STIR Short-tau inver-
sion recovery (STIR) and T2 weighted image). The 
signal increase is due to oedema and blood flow, usually 
from the muscle-tendon junction, which expands along 
the muscular fascicles producing a classic ‘bird pen’ 
pattern. The lesion extension has a maximum diameter, 
however, smaller than that of a secondary bundle (ie, 
less than 5 mm). In the indMI I° perifascial fluid is also 
visible.
Prognosis
With optimal treatment the prognosis for RFPTC is about 
15 days.
Grade II lesion (indMI II°)
In opposite to US, MRI examination, thanks to its 
high-contrast gradient, allows to differentiate indMI II° 
in three variants: types A, B and C. The indMI II° (in its 
variants A, B and C) must be considered a macroscopic 
structural damage.
Clinical-anamnestic criteria
The clinical-anamnestic criteria identified for the US 
exam remain valid.
MRI criteria
Macroscopic alterations of muscular architecture can 
be observed within the lesion zone. The extension of 
the lesion involves more than one secondary bundle (ie, 
greater than 5 mm). Frequently, the perifascial liquid 
may be very abundant and may expand in accordance to 
the anatomical structure of the injured muscle, allowing 
to easily see the secondary fascicles remaining structur-
ally intact.
A further classification of the grade II lesions can be 
performed by staging the extension of the lesion (and 
indirectly the number of secondary fascicles)36 43:
i. Grade II lesion A-type (indMI II° A) injury involv-
ing less than one-third (ie, less than ~35%) of the 
muscular cross-sectional area (CSA).
ii. Grade II lesion B-type (indMI II° B) injury involv-
ing more than one-third but less than two-thirds (ie, 
between ~35% and ~65%) of CSA.
iii. Grade II lesion C-type (indMI II° C) injury involving 
more than two-thirds (ie, between ~65% and~85%) 
of CSA.
The prognosis for RFPTC (with optimum treatment) is 
~20 days for an indMI II° A, ~40 days for an indMI II° B 
and ~60 days for an indMI II° C.
Grade III lesion (indMI III°)
Generally, third-degree lesions are observed more 
frequently at the origin of the free proximal tendon, while 
they are less frequent distally. Grade III lesions are rare 
and represent on average 3% of all lesions observed.51 
Surgery is rarely needed and is normally performed in 
the case of avulsion trauma with a retraction greater 
than 2–3 cm.3 6 45 IndMI III° is a macroscopic structural 
damage.
Clinical-anamnestic criteria
The clinical-anamnestic criteria identified for the US 
exam remain valid.
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MRI criteria
A third-degree injury involves more than 85% of the CSA 
with a haematoma that fully fills the gap of the lesion. 
The secondary bundles show a clear ripple and retrac-
tion.
Prognosis
With optimal treatment the prognosis for RFPTC is on 
average between 60 and 90 days.
direct mI
DirMIs are divided into contusions and lacerations. 
The contusions are caused by the impact of a generally 
rounded foreign body on the muscle surface. The lacera-
tions are the result of the effect of a sharp body (cutting 
wounds) or the penetration of a pointed body (tip inju-
ries) in the muscle.
As far as the second case is concerned, for the tears, CC 
does not propose a specific classification of their gravity. 
In this category only contusions were considered.
The CC adopted a classification of dirMI divided into 
three categories: minor, moderate and severe; this classifi-
cation is mainly based on functional (clinical) evaluation. 
All the three categories of dirMI are to be considered a 
structural lesion.
i. Minor dirMI (dirMI GMi) where movement is 
possible for more than half of the range of motion 
(ROM) of the involved joints is possible. The US and 
MRI exam show the presence of a limited haemato-
ma. The prognosis (with optimal treatment) is be-
tween 3 and 10 days.
ii. Moderate dirMI (dirMI GMo) where movement is 
possible for less than half but more than one-third of 
the entire ROM of the involved joints is possible. The 
US and MRI exams show the presence of a diffuse 
haematoma. The prognosis (with optimal treatment) 
ranges from 10 to 50 days depending on the exten-
sion of the haematoma itself.
iii. Severe dirMI (dirMI GS) where the movement is 
possible for less than one-third of the total range 
of movement of the involved joints is allowed. The 
US and MRI exam show the presence of widespread 
haematoma and muscle fibre crushing. The progno-
sis (with optimal treatment) is between 50 and 70 
days.
On examination of US and MRI, the dirMI does not 
differ significantly from the indMI, showing a more 
or less circumscribed oedema or haematoma, with a 
possible discontinuity of the secondary fascicles. In the 
US examination, the appearance of a haematoma is quite 
variable and depends on the trauma dating. A recent and 
high-pressure haematoma is sometimes more echogenic 
because of its high cellular content and can, therefore, 
remain difficult to differentiate from muscle tissue. In any 
case, it important to note that a haematoma in the first 24 
hours post-trauma may have a very variable appearance, 
from not echogenic at all or hypoechogenic to a frankly 
hyperechogenic appearance. Finally, in the following 2–3 
days the haematoma moves to hypoechogenicity or not 
echogenicity appearance.52
It should be noted that in dirMI the extent of haema-
toma is not necessarily correlated, as opposed to indMI, 
with the severity of the lesion and consequently with the 
severity of the prognosis. In fact, a direct trauma causes 
vascular damage and internal bleeding. Structural fibre 
lesion is rare since the contusing force tends to crush 
them.43 In other words, a diffused haematoma can only 
be caused by a rupture of the vessels and not necessarily 
by the loss of continuity of muscle fibres, as it is the case 
with indMI. For this reason, in dirMI the prognosis is 
usually better than the indMI of equal size.43 45
The timing of the imaging exam
There is no consensus in the literature as to the optimal 
timing to perform the MRI or the US after the injury 
event.42 53 As far as the US examination is concerned, the 
timing of the exam execution that is more consensual 
would seem to be ~48 hours from the injury.41 50 54 There-
fore, this is the indication provided by the CC.
Regarding MRI examination, some authors55 demon-
strated the signal invariance in the fluid-sensitive 
sequences within the so-called ‘acute phase’, that is, 
during the first 7 days after injury. However, in the 
present study, the MRI signal recorded in the fluid-sensi-
tive sequences is considered in its entirety, that is, without 
differentiating the oedema from the blood. Indeed, one 
of the most important parameters regarding the choice 
of timing of the imaging is that it can accurately discern 
whether the fluid content inside and around the area is 
oedema and/or haematic in nature. This aspect is funda-
mental when it comes to differentiating an indMI 0° from 
an indMI I°, given in particular the important prognostic 
difference between the two different types of lesion (8 
days vs 15 days) and the resulting obvious diversity of the 
rehabilitation programmes to be adopted. As already 
mentioned, such differentiation is only possible through 
MRI assessment, provided that it is carried out within 
a proper ‘time window’. Based on studies performed 
on brain bleeding states, and in absence of any study 
concerning muscle haematoma in different states,56–61 
this CC suggests that the ideal observation window lies 
between the third and fifth postlesion days. During this 
period, it is possible to differentiate the oedema from the 
blood by comparing the T1 and the T2 sequences.56–61 In 
any case, it is important to note that muscle haematoma 
sometimes shows, at MRI examination, a rather variable 
appearance compared with the lesion dating; therefore, 
the appearance may sometimes differ from that observed 
in a haematoma at the cerebral tissue level.56 57 61 It is, 
therefore, advisable to exercise caution in data interpre-
tation.
seCTIon 3. summAry of mI ClInICAl AssessmenT 
doCumenT Consensus
Despite the increasing imaging utilisation in MI diagnos-
tics, clinical skills remain a fundamental point. According 
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to the CC conclusion, clinical evaluation must basically 
consist of three distinct, but highly complementary 
phases:
i. Anamnesis (AN; history). 
ii. Inspection (IS). 
iii. Clinical examination.
Anamnesis
AN is a fundamental part of the clinical evaluation. In 
order to rationalise the anamnestic examination, the CC 
recommends to follow the key points below:
i. Pay attention whether in the past or recent AN similar 
lesion to the one currently evaluated has occurred, 
or in an anatomically adjacent area: this finding is 
crucial to identify possible recent or late reinjuries.
ii. The fact that the patient can easily recall of the 
moment of trauma and indicates with exact accu-
racy the precise area of pain is highly suggestive of 
a structural muscular injury. This diagnostic suspi-
cion could be confirmed by the fact that the athlete 
has failed to complete the rest of training session or 
competition.
iii.   Conversely, a cramping sensation, though progres-
sive, would be strongly suggestive of an ultrastructur-
al lesion.
iv. The young age and the particular anatomic location 
of the pain site (anterior superior iliac spine, anterior 
inferior iliac spine, ischial tuberosity) may be highly 
suggestive of the diagnosis of an apophyseal injury.
Inspection
IS is the second phase of the clinical evaluation. The CC 
recommends the following key points to be respected 
during the IS:
i. Check for swelling.
ii. Check for the presence of haematoma (strongly sug-
gestive of the indirect lesion) or ecchymosis (strongly 
suggestive of direct trauma).
iii. Check for the presence of gap or clear muscle 
retraction.
iv. Check for changes in the muscular profile in the 
region of the suspected lesion in comparison to the 
contralateral muscle.
Clinical examination
A proper clinical examination must be based on the 
following points:
i. Palpation.
ii. Checking of ROM.
iii. Stretching.
iv. Functional manoeuvres.
Palpation
The palpation exam (PE) requires specific skill set and 
experience of the clinician. The PE shall be conducted 
in two ways:
i. PE mode 1: The patient is positioned in a way that 
the examined muscle is in a slightly elongated posi-
tion (hence slightly contracted eccentrically). 
ii. PE mode 2: The muscle to be examined must be 
completely relaxed. The PE should be repeated sev-
eral times, according to the two above-mentioned 
modalities, both on the entire muscle belly and on 
the area/point of pain indicated by the patient. 
The clinician should get information, obvious-
ly subjective, from the skin, subcutaneous tissue, 
fascia and muscle. The PE should be performed, 
when applicable, in a comparative manner and in 
both modalities described above, exerting a mod-
erate pressure, and in a proximal-distal direction 
and vice versa, always following the orientation of 
the fibres.
The PE aims to verify:
i. The tone of the muscles affected by the alleged le-
sion compared with the contralateral one. In addi-
tion, it is of utmost importance to check the tone 
of the muscles adjacent to the presumably injured 
one, as a tone alteration may suggest a high-grade 
lesion.18 32
ii. The presence of gap or clear muscle retraction.
iii. The existence of stiff zones.
iv. The existence of previous fibrotic areas or altered 
myofascial adhesion.
v. The existence of painful areas or otherwise 
impaired perception by the patient.
Checking of ROM
The ROM of the proximal and distal joints (when appli-
cable) to the injured muscle should be checked (eg, hip 
and knee in case of a rectus femoris lesion).
Stretching
A stretching of the injured muscle should be performed 
in the following modalities:
i. Active modality.
ii. Passive modality.
Generally, a structural lesion results in pain on both 
passive and active stretching, while in a functional 
pathology (such as the DOMS) stretching may provide a 
pleasant feeling to the patient.
Functional manoeuvres
The injured muscle should be tested in three ways:
i. Maximum isometric contraction.
ii. Concentric contraction of medium intensity against 
the operator’s resistance. 
iii. Medium effort eccentric contraction against opera-
tor’s resistance with no pain.
Quantification (from 0 to 10) of the perceived pain 
in accordance with the visual analogue scale62 will be 
required for each type of contraction.
Finally, in order to facilitate a summary of the 
main information of the clinical evaluation exam, CC 
proposes the adoption of two dedicated tabs of which 
we provide an example in online supplementary annex 
1 and annex 2.
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seCTIon 4. summAry of mI ConservATIve TreATmenT 
doCumenT Consensus
In the fourth document, all the non-surgical treatments 
of MI are considered as conservative treatments. The 
fourth document provided the following points:
i. The conservative treatment of indMI.
ii. The conservative treatment of dirMI.
iii. The physical therapy into the conservative treatment 
of MI.
iv. The pharmacological treatment of MI.
The treatment of doms, fImd and grade 0 lesion (indmI 0°)
While there is no evidence in the literature concerning 
the conservative treatment of DOMS, FIMD and indMI 
0°, the CC merely proposes treatment guidelines based 
on expert advice (level of evidence IV).
It is possible to summarise the main points of the 
rehabilitation programme as follows:
i. Suspension or reduction of the functional load 
until total or partial resolution of symptoms.31 63
ii. Contrast therapy (hot/cold).64 65
iii. Hydrokinesitherapy.64 65
iv. Endogenous thermotherapy.66
v. Massage.67 68
It is important to note that, despite the controversy in 
literature69–71 of the above-mentioned treatment, many 
athletes are seeking them because they feel their bene-
fits.67 68
Treatment guidelines according to the biological tissue repair 
steps for grade I indirect lesions (indmI I°) and onwards
As already discussed, muscle tissue repair/regen-
eration process is completed in a longer or shorter 
period depending on the severity of the lesion. 
During this period, there are well-defined biolog-
ical phases (first phase of destruction, the second 
phase of repair/regeneration and third phase of 
remodelling).31 63 The CC, therefore, recommends a 
three-phase break-up rehabilitation protocol. Each of 
these phases must be characterised by a well-defined 
type of muscular contraction that is consistent with 
the biological condition observed within the injured 
area.31 63 Therefore, the rehabilitation programme 
should be set as follows:
The first phase (approximately between the second and the 
fifth to seventh postlesion days)
The biological situation within the injured area
At the beginning of the first phase (second postle-
sion day), the necrotised parts of the muscle fibres are 
removed by the macrophages. At the same time, the 
formation of the scarring connective tissue within the 
central lesion zone (CZ; ie, the gap of the lesion) by 
fibroblasts starts. At the end of the first phase (approxi-
mately seventh postlesion day), the repairing processes 
of the muscle cells extend beyond the old basal laminae 
cylinders in the CZ and begin to penetrate through the 
scar zone.10 27 31 32 63 72 73
Type of contraction in the first phase
Considering that the first 5–7 postlesion days are char-
acterised by the fact that the CZ has not yet developed 
a sufficiently dense and compact scarring connective 
tissue, the major risk in this period is that an excessive 
muscle contraction, especially with eccentric modality, 
increases the already existing lesion gap. Therefore, 
the type of contraction recommended in this first 
phase is an isometric modality. In fact, during the 
isometric contraction there is no myofilaments slip-
page and, therefore, there is no macrochange of the 
muscle length. For this reason, the CZ lesion gap is not 
structurally stressed.74 The intensity of the isometric 
contraction required must, however, remain below the 
threshold of pain.63
In this first phase, the CC also recommends:
i. In the immediate postinjury period (24–72 hours) it 
is advisable to apply the PRICE (Protection, Rest, Ice, 
Compression, Elevation) principle.75 
ii. It is possible to consider having a short rest period 
and/or relative immobilisation immediately after the 
injury. This rest period optimises the formation of 
connective tissue by fibroblasts within the CZ, there-
by reducing the risk of recurrences.31 63 76 However, 
rest and immobilisation should be reduced to only 
the first postlesion days (3–5 days).31 63 76
iii. In the first 72 hours postlesion, physical therapies 
that induce endothermia should be avoided in 
order to avoid the possible increase in blood 
extravasation.
iv. All forms of massage on the affected area should be 
avoided. The practice of massage is allowed only af-
ter the completion of tissue healing processes.77
v. If there is an excessive haematoma formation with-
in the injured area, it is advisable to proceed to an 
echo-guided aspiration before the haematoma or-
ganisation.76 78
second rehabilitation phase (approximately between 8th and 
14th postlesion days)
Clinical and functional data and imaging techniques are 
the criteria for proceeding from the first to the third 
phase of rehabilitation.
Clinic criteria
i. Resolution of swelling, if initially present.77 79
ii. Absence of pain in response to maximal isometric 
contraction.77 79 
iii. Absence of pain in response to end-range stretching 
tests carried out in the active and passive modes.49 77 79
iv.  Complete ROM of the joints involved in the move-
ment.77 79
Imaging criteria
i. Reduction of the lesion gap as observed with US or 
MRI imaging.80 81
ii. The presence of granulation repair tissue within the 
CZ as revealed by the US.80 81
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The biological situation within the injured area
At this stage, the scar zone in the CZ is further condensed 
and reduced in size, and myofibres fill the residual gap of 
the CZ.10 27 31 32 63 72 73 During this phase, the granulation 
tissue gains compactness and elasticity.82 However, the 
possible weak points of the lesion repair in this and the 
next phase44 45 could be:
i. Immature scar tissue within the CZ.80
ii. Healthy muscle tissue adjacent to the CZ which can 
be overtensioned.80
Type of contraction in the second phase
The CC recommends that the second phase of treatment 
respects the following points:
i. The introduction of progressively intense exercises 
based on concentric contractions. During a concen-
tric contraction, the bulk of the muscle shortens due 
to the sliding motion of the myofilaments with a rel-
atively constant force proportional to the external 
load. Subsequently, the CZ is not subjected to trac-
tion and the jagged muscle edges, undergoing reor-
ganisation/repair, avoiding diastasis.83
ii. The concentric contraction can be manual at the 
beginning and subsequently with isotonic equip-
ment (ie, Olympic weightlifting devices).84
iii. The eccentric (ie, negative) phase of the move-
ment must, in all cases, be reduced to the minimum 
possible intensity.77
iv. Since there is evidence85 that a rehabilitation 
protocol, following an indMI which includes exer-
cises aimed to stabilise and strengthen the ‘core’ 
muscles (in particular abdominal, quadratus lum-
borum and paravertebral muscles) yields better re-
sults (in terms of reduced relapses and in an earlier 
return to sport), a ‘core stability program’ should 
be systematically introduced in the rehabilitation 
plan.86
v. Stationary bike and deloaded run can be introduced 
during this phase.79
Third rehabilitation phase (~14th–21st day, postinjury)
Clinical data and imaging techniques are the criteria for 
proceeding from the second to the third phase of reha-
bilitation.
Clinical criteria
i. The absence of pain in response to concentric con-
traction performed at increasing intensity against re-
sistance performed by the physiotherapist.77 79 
ii. The absence of pain in response to submaximal 
eccentric contraction.77 79
Imaging criteria
i. The substantial disappearance of the lesion gap on 
US or MR examination.80 81 
ii. The presence of compact granulation repair tissue 
within the CZ as revealed by US or MR.80 81
The biological situation within the injured area
In this phase, the myofibres intertwining is effectively 
completed by the interposition of a small amount of 
scar tissue. The remodelling phase may last more than 
60 days, depending on the anatomical extent of the 
injury.
Treatment during the third week of the postinjury 
should, therefore, respect the following points:
i. The inclusion of isokinetic exercises76 followed by: 
ii. The inclusion of elastic resistance exercises where 
the intensity of the eccentric phase is progressively 
increased, followed by77 79:
iii. Exercises predominantly based on eccentric contrac-
tions of progressively increasing intensity.77 79
iv. The introduction of stretching. Stretching must be 
introduced gradually and exercises must not cause 
the onset of pain. The time of elongation initially 
is 10–15 s and subsequently up to 1 min, in order 
to induce a durable, and not just a transient, plastic 
deformation within the area of structural reorganisa-
tion.77 79 87
v. Running may be introduced during this phase, on 
the condition that dynamometric values of the in-
jured muscle have been reinstated to at least 70% of 
the preinjury level or that of the opposite limb.77
vi. Sport-specific exercises can be introduced with 
caution at the end of the third phase.77
phase duration
The duration of each phase is consistent with the 
dynamics of the healing processes occurring in the 
muscle tissue affected by the injury and therefore, the 
duration of each of the three phases is directly related to 
the severity of the injury. In other words, for every grade 
3 lesion, the duration of each of the three phases will 
vary. The duration of each phase has to be determined 
ad personam, in accordance with the clinical and imaging 
criteria required for proceeding from one phase to the 
next. Therefore, although rehabilitation indMI I°, indMI 
II° and indMI III° will be subdivided into three phases, 
the duration of phases will be different, and progression 
is not time based, but clinical, functional and imaging 
criteria based.77 79
The conservative treatment of haematoma
Since the blood loss causes the formation of a 
haematoma, it is necessary to distinguish between 
intermuscular haematoma (interH) and intramuscular 
haematoma (intraH).
interH: In this case, the fascia appears to be injured so 
that the blood can be released from the muscle belly. 
Pain generally persists for a period ranging from 24 to 
48 hours.8889
intraH: In this case, the muscle fascia remains intact 
and the blood extravasation remains confined within the 
injured muscle. Since the blood collection within the 
muscle produces an osmotic gradient, the swelling can 
persist, or increase, beyond 48 hours postlesions.90
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The CC recommends that the treatment of the haema-
toma follows the following points:
i. Into the case of intraH, the PRICE principle needs 
to be changed. Indeed, into the intraH compression 
therapy should be avoided in order to avoid the onset 
of a compartmental syndrome.22 Furthermore, there 
is no need to apply the principle of the ‘protection’ 
of the injured limb. On the contrary, in order to fa-
cilitate the haematoma reabsorption in intraH, early 
mobilisation is preferable since from the second-day 
postlesion.79 91
ii. In the presence of excessive haematoma formation, 
it is advisable to proceed to an ultrasound-guided 
aspiration before the solid haematoma organisa-
tion.76 78 
iii. The so-called ‘contrast therapies’ (ie, the alternate 
administration of hot and cold in order to speed up 
the absorption of haematoma) can be initiated only 
at the end of the haemorrhagic phase, so usually not 
before 72 hours.92
iv. Massage must be avoided in the first postlesion days, 
in order to avoid a possible exacerbation of the hae-
morrhagic process.79 Massage can be started when 
the haematoma has completely disappeared.79
Instrumental therapy in the conservative treatment of MI
In the first postlesion days, it is of paramount importance 
to allow the implantation of muscle resident stem cells 
(MRSC) inside the injured area.93–95 The MRSC implant 
process is strongly dependent on the injured muscle 
angiogenesis process. This process is stimulated by both 
voluntary exercise and neuromuscular electrostimula-
tion (NMES).93–95 For this reason, the use of NMES by 
promoting an early angiogenesis in the post-traumatic 
regeneration phase could increase both the presence of 
MRSC and postnatal muscle-derived stem cells (MDSC) 
resulting from the vascular endothelium. In fact, some 
authors have advanced the hypothesis that MDSCs 
originate from blood vessels.96–98 The use of NMES for 
vascularisation should be encouraged until the end 
of the regeneration phase (ie, up to about the third 
postlesion week).99 100
Ultrasound therapy 
There is limited evidence that ultrasound therapy (UST) 
is able to increase the levels of basic fibroblastic growth 
factor and vascular endothelial growth factor (VEGF).101 
The use of UST in MI is justified by the fact that tissue 
micromassage induced by the UST frequencies can 
generate an antalgic effect.102 However, it is important 
to note that UST can inhibit the expression of the RNA 
messenger (mechano growth factor (MGF) mRNA).102 
The MGF mRNA plays an important role in the 
insulin-like growth-1 (IGF)-1 upregulation mechanism. 
Therefore, it is advisable not to use UST in the first 24 
hours postlesion.102 In summary, UST may be recom-
mended in the conservative treatment of MI after the 
first 24 hours postinjury.101 102
Laser therapy 
Many studies have shown that laser therapy (LT) can 
reduce the inflammatory process of the damaged 
muscle tissue,103 speed up the tissue regeneration/
repair processes by stimulating myogenic processes,104 
optimise the oxidative metabolism by increasing ATP 
synthesis105–107 and stimulate the synthesis of RNA and 
regulatory protein cycles in cell proliferation.108 Finally, 
LT could increase the expression of VEGF.109 110 There-
fore, the use of LT in the treatment of MIs appears to be 
justified by sufficient evidence.111
Hyperthermia (endogenous thermotherapy)
Hyperthermia therapy (HT) (ie, microwave diathermy) 
increases the temperature of the deep tissue up to 41°C–
45°C, through electromagnetic energy. HT has proven to 
be able to stimulate the tissue repair processes, diminish 
pain symptoms, increase tissue flexibility and reduce 
muscular and joint stiffness.112 113 Some studies point 
out its effectiveness even in the specific field of skeletal 
muscle repair/regeneration processes.112–117 HT may also 
facilitate the resolution of haematoma following MI.118 
Furthermore, HT increase increases  pain threshold 
through a direct action of heat on free  nerve endings119 
and trunks120 sufficiently to block the transmission of 
pain.119 120 Finally, HT reduces the muscle spasm resulting 
from MI contributing to the pain decreasing.117 121 122 
Therefore, for CC experts’ opinion, the use of HT in the 
treatment of MI is justified by a sufficient evidence.
Hyperbaric oxygen therapy
Currently, in the literature, there is a total lack of evidence 
on the effectiveness of hyperbaric oxygen therapy (HOT) 
in the MI conservative treatment, both indirect and 
direct. Therefore, the HOT needs further evidence to 
prove its effectiveness in MI treatment.
Extracorporeal shock wave therapy
Extracorporeal shock wave therapy (ESWT) is a ‘mechan-
otherapy’, whose biological effects have been now widely 
described: modulation of inflammation and macro-
phages activity, angiogenesis and tissue-specific growth 
factor (GF) induction, SC activity stimulation, besides 
antioedema and antinociceptive effect.123–125 Based on its 
‘trophic’ effects and in accordance with the Consensus 
Statement of the International Society for Medical 
Shockwave Treatment126 regarding clinical indications, 
the CC suggests to apply ESWT in DOMS, reserving to 
‘ESWT skilled hands’ its application after muscle lesions 
as possible adjuvant therapy, in order to reduce oedema 
and pain, improve healing and accelerate remodelling of 
tissue fibrosis regardless of the degree of the injury.123–127
pharmacological treatment of mI
The most commonly used pharmacological therapies 
have been taken into consideration by the CC. The CC’s 
recommendations in this specific field can be summarised 
as follows:
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Non-steroidal anti-inflammatory drugs
Non-steroidal anti-inflammatory drug (NSAID) prescrip-
tion in the early postinjury period, especially in the case 
of a medium to severe MI (II°–III°), can be considered 
as a justified medical treatment.128 It should be remem-
bered, however, that there is still no evidence of the 
benefits and the adverse effects that the intake of non-se-
lective NSAIDs may provide.129
The use of analgesic drugs
The most commonly used analgesic drug is parac-
etamol.129 Its analgesic effect is mainly related to the 
action on the systems involved in pain modulation, such 
as serotonin system. Paracetamol does not act at periph-
eral level and therefore does not have anti-inflammatory 
activity. Some studies recommend the use of analgesics 
for low-intensity pain in neuromuscular disorders in the 
first postlesion days.130 In conclusion, the CC suggests 
that analgesics can be used in case of pain in the first 
postlesion days.
The use of calcium chelants
Chelation therapy is a drug therapy utilising chelation 
to treat some forms of intoxication due to heavy metals. 
In the case of MI, chelators may limit the calcium over-
load phase (calcium is an alkaline earth metal). The 
most widely used and well known of chelants is EDTA. 
EDTA would seem to be able to limit the histopatholog-
ical changes present in the context of muscular lesions.131 
However, the use of calcium chelants needs further 
evidence to be justified for the treatment of MIs.
The use of corticosteroids
The use of corticosteroid drugs should be avoided. 
Indeed, among different adverse effects,67 they involve 
delayed absorption of haematoma, increased necrosis in 
the injured myofibrils, delay in muscle tissue regenera-
tion processes and loss of muscle strength.132
The use of muscle relaxant drugs
The use of muscle relaxant drugs for a limited period 
could, in theory, reduce, or at least contain, the self-aggra-
vation stage of the lesion. In any case, CC recommends 
that the use of muscle relaxants requires further evidence-
based studies regarding their efficacy in MI treatment.
Actovegin
Actovegin is a deproteinised derivative—ultrafiltrate 
of calf serum from animals under 8 months of age. 
It is important to remember that the use of Actovegin 
may, although in rare cases, have serious adverse effects 
(anaphylactic shock with multiorgan failure in a cyclist 
after intravenous administration of Actovegin),133 also if 
in effect this effect is most likely not due to Actovegin 
administration but due to a bacterial/infection contam-
ination. In the literature , it is still yet to define the 
Actovegin’s active compounds,134 in any case current 
literature suggests that Actovegin shows antioxidant 
and antiapoptotic properties, and may also have an 
upregulating action on macrophage responses following 
muscle repair.134 However, the Actovegin’s clinical efficacy 
is supported by only one new original research article.135 
Finally, the CC, after the examination of the current liter-
ature, believes that Actovegin needs further evidence to 
demonstrate its efficacy in the MI treatment.133–139
Traumeel
Traumeel is a homeopathic medicine marketed in Italy 
under the name of Arnica compositum (most recently 
under the name of Hell Traumeels), in the form of a gel 
or solution for injection. In literature, there are studies 
(randomised controlled trials) that show its efficacy 
in the reduction of pain and swelling following MIs,140 
in rotator cuff syndrome141 and in ankle and knee 
sprains.142 143 Finally, Traumeel has proven to be a well-tol-
erated product with little adverse effects.144–146 However, 
since Traumeel is a homeopathic product, this CC still 
expresses a certain perplexity about its effectiveness and 
hopes that further evidence in the future will confirm its 
therapeutic validity.
Losartan
Losartan is an angiotensin II antagonist drug used to 
treat essential hypertension. Some studies show that 
losartan, if used in a time period ranging from 3 to 7 
days on mouse model,147 in addition to platelet rich 
plasma (PRP) therapy (PRPt),148 is able to reduce fibrotic 
processes in MI, promote tissue repair/regeneration 
processes and stimulate angiogenesis. Further and more 
thorough studies will have to demonstrate the effective-
ness and safety in humans.
The use of mesenchymal stem cells
Mesenchymal stem cells (MSC) are adult, immature, 
undifferentiated and multipotent SCs that originate from 
mesoderm, and which can be extracted from the adipose 
and synovial tissues, blood, skeletal muscle, umbilical cord, 
placenta and bone marrow.28 The Australasian College 
of Sport and Exercise Physicians, formulating a change29 
to the previously stated position statement on the use of 
MSCs,28 strongly advised to restrict the use of MSCs only into 
well-controlled clinical research trials. This recommenda-
tion is the result of serious complications (glioproliferative 
lesion of the spinal cord arising from the use of MSCs).149 
Therefore, the CC does not advocate the use of MSCs as 
part of MI care, as long as scientific evidence does not 
confirm its effectiveness and safety.
The use of platelet GFs
The methodology using PRP is based on the rationality 
that GFs contained in platelets stimulate the proliferation 
of skeletal muscle cell progenitors, guide cell differenti-
ation and modify the local inflammatory response.150–154 
On this rationale of application, research investigating the 
efficacy of PRP in cartilage, bone and muscular-tendon 
diseases was carried out.150–154 However, there are many 
problems actually still unresolved as well as many doubts 
about the actual efficacy of PRPt.
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Synthetically, the various fields of investigation still in 
progress can be summarised as follows: 
i. Nomenclature and classification.155–158 
ii. Standardisation and preparation of the prod-
uct.153 159 160 
iii. The specific indications of PRPt.161 162 
iv. The release kinetics of the various GFs.163–165 
v. The timing of administration.163–165
After discussing the above points, CC formulates the 
following recommendations:
i. As there is currently no consensus concerning the 
PRP classification,155–158 166 a universally shared classi-
fication of all different autologous blood and plasma 
preparations of PRPt has to be urgently developed.
ii. Since the effects of various PRP preparations in func-
tion of their different formulations are not yet well 
understood,153 159 160 166 there is a need for a consen-
sus on standardised product preparation.
iii. Since a key point in PRPt is the full understanding 
of the different roles of the various GFs and differ-
ent cytokines within the different biological con-
texts considered,161 162 167 168 the CC underlines the 
strong need for further major studies to clarify the 
specific indications of different types of GF and cy-
tokines present in different types of PRPt currently 
proposed.
iv.  Since any pathological conditions may have a ther-
apeutic window within which PRPt would be able to 
make the greatest benefit,163–165 the CC hopes that 
further studies will be implemented in the future 
to elucidate the kinetics of release and activation of 
cytokines and GFs, and the subsequent activation 
methods according to different tissues and differ-
ent pathological conditions.
v. As the optimum timing of PRP administration 
remains an essentially unknown aspect,163–165 the CC 
underlines the strong need for further high level 
of evidence studies to clarify the timing of admin-
istration, according to the specific indications of 
the different types of GF and cytokines present in 
different types of PRPs currently proposed.
CC ConClusIons
The main strength of the Italian CC on guidelines for 
conservative treatment of lower limb injuries in athlete 
was the presence of recognised leading experts in this 
ﬁeld with different backgrounds. This multidisciplinary 
expert attendance guaranteed a deep and comprehen-
sive approach to the topic.
During the CC some important points of discussion and 
reﬂection emerged. They can be summarised as follows:
i. The CC underlined the importance of a full 
understanding of biological and biomechanical 
mechanisms of MI aetiology. This is a key point in 
applying rational conservative treatment protocols 
for MI.
ii. The presented MI classification is reproducible, 
clearly distinct, easy to memorise, concise, easy to un-
derstand and linked to prognostic factors.
iii. The CC referred clear references concerning the 
presented clinical evaluation of MI.
iv. The CC presented a rehabilitation programme plan 
conceived in accordance with the biological repair 
phases of muscle tissue.
v. The CC presented a clear overview of the state 
of the art of pharmacological and instrumental 
therapy concerning MI.
fuTure dIreCTIons
The CC hopes in the future to develop and study the 
following points:
i. A greater control of the actual effectiveness and 
scientific rationality of the application of physical 
therapy regarding MI.
ii. The implementation of research projects searching 
for more evidence regarding pharmacological ther-
apies in general and especially regarding the use of 
PRPt and MSCs.
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